CAPRELSA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Vandetanib.
Product ID | 0310-7840_e7eebdc7-a867-4d35-9b5b-2c1829a4e778 |
NDC | 0310-7840 |
Product Type | Human Prescription Drug |
Proprietary Name | CAPRELSA |
Generic Name | Vandetanib |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2011-07-25 |
Marketing End Date | 2020-05-31 |
Marketing Category | NDA / NDA |
Application Number | NDA022405 |
Labeler Name | AstraZeneca Pharmaceuticals LP |
Substance Name | VANDETANIB |
Active Ingredient Strength | 300 mg/1 |
Pharm Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Cation Transporter 2 Inhibitors [MoA] |
NDC Exclude Flag | N |
Marketing Start Date | 2011-07-25 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022405 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2011-07-25 |
Marketing End Date | 2020-05-31 |
Ingredient | Strength |
---|---|
VANDETANIB | 300 mg/1 |
SPL SET ID: | 4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0310-7820 | CAPRELSA | Vandetanib |
0310-7840 | CAPRELSA | Vandetanib |
58468-7820 | CAPRELSA | Vandetanib |
58468-7840 | CAPRELSA | Vandetanib |
58468-7860 | CAPRELSA | Vandetanib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
CAPRELSA 85360880 4211262 Live/Registered |
GENZYME CORPORATION 2011-06-30 |
CAPRELSA 78588611 3092679 Live/Registered |
GENZYME CORPORATION 2005-03-16 |